

## Special Issue

# Antimicrobial Susceptibility and Clinical Findings of Anaerobic Bacteria, 2nd Edition

### Message from the Guest Editor

The first edition of the Special Issue “Antimicrobial Susceptibility and Clinical Findings of Anaerobic Bacteria” was published in 2021. This was a successful collection that comprised nine excellent papers. The success of this Special Issue encouraged us to open a second edition covering the same topic. As a continuation of the first Special Issue, this second edition aims to contribute to the knowledge regarding the percentage of the resistance of clinically significant anaerobes in different settings, and to determine the key clinical characteristics of these patients. Routine antimicrobial susceptibility testing for anaerobes provides information about the global situation, allowing empirical therapies to be selected in accordance with the local data on resistant strains.

---

### Guest Editor

Dr. Fernando Cobo

Department of Microbiology, Hospital Virgen de las Nieves, Avda Fuerzas Armadas, Granada, Spain

---

### Deadline for manuscript submissions

15 March 2025



## Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.3  
CiteScore 7.3  
Indexed in PubMed



[mdpi.com/si/201378](https://mdpi.com/si/201378)

*Antibiotics*

MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.3  
CiteScore 7.3  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1  
(General Pharmacology, Toxicology and Pharmaceutics)